Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

by · The Markets Daily

Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 110,600 shares, a decline of 38.1% from the November 30th total of 178,800 shares. Based on an average daily volume of 83,200 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.6% of the company’s stock are short sold.

Institutional Trading of Aileron Therapeutics

Large investors have recently made changes to their positions in the stock. University of Texas Texas AM Investment Management Co. purchased a new stake in Aileron Therapeutics in the second quarter worth approximately $4,925,000. Nantahala Capital Management LLC boosted its stake in shares of Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after buying an additional 209,367 shares during the last quarter. Warberg Asset Management LLC purchased a new stake in shares of Aileron Therapeutics during the 2nd quarter valued at about $86,000. KG&L Capital Management LLC purchased a new position in shares of Aileron Therapeutics in the third quarter worth approximately $46,000. Finally, Sigma Planning Corp grew its position in shares of Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after acquiring an additional 86,185 shares during the period. 90.89% of the stock is currently owned by institutional investors.

Aileron Therapeutics Price Performance

Shares of Aileron Therapeutics stock traded down $0.02 during trading on Friday, hitting $2.23. 135,807 shares of the company’s stock traded hands, compared to its average volume of 79,391. Aileron Therapeutics has a 1 year low of $1.61 and a 1 year high of $7.42. The business has a 50-day simple moving average of $2.90 and a 200-day simple moving average of $2.87. The stock has a market capitalization of $48.32 million, a P/E ratio of -0.71 and a beta of 2.22.

About Aileron Therapeutics

(Get Free Report)

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Featured Articles